Armata Delays 2025 Results, Gains FDA QIDP for AP-SA02 and Commissions cGMP Facility
Armata delayed its Q4 and full-year 2025 financial results, now expecting to file its Annual Report on Form 10-K by March 31, 2026. The FDA granted QIDP status to AP-SA02, cleared a Phase 3 trial design and the company commissioned a 56,000 sq ft cGMP facility ahead of a H2 2026 study start.
1. Financial Reporting Delay
Armata announced it will delay the release of its fourth quarter and full-year 2025 financial results and now anticipates filing its Annual Report on Form 10-K by March 31, 2026, citing the need for additional time to complete its financial statements.
2. FDA Regulatory Progress
The FDA granted Qualified Infectious Disease Product designation for AP-SA02 for intravenous use in complicated Staphylococcus aureus bacteremia and provided an End-of-Phase 2 written response that aligns Phase 3 study design, while a Fast Track designation request is pending to expedite regulatory review.
3. Manufacturing Scale-Up
The company formally commissioned its state-of-the-art 56,000 sq ft cGMP manufacturing facility in Los Angeles, which includes 10,000 sq ft of clean rooms, an automated fill and finish suite, and quality control labs, completing full production runs to support clinical trials and future commercialization.
4. Phase 2a diSArm Efficacy Data
At a late-breaking oral presentation, AP-SA02 combined with Best Available Antibiotic Therapy achieved a 100% response rate without relapse at day 12 and day 28 compared to approximately 75% in the control group, showing rapid blood culture clearance, shortened ICU stays and strong tolerability.